Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza. (2020)
Attributed to:
Cytoplasmic tail interactions of the influenza M2 protein with lipid and protein.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1371/journal.ppat.1008716
PubMed Identifier: 32780760
Publication URI: http://europepmc.org/abstract/MED/32780760
Type: Journal Article/Review
Volume: 16
Parent Publication: PLoS pathogens
Issue: 8
ISSN: 1553-7366